Gritstone bio Shares Jump After Updated Overall Survival Data From Colorectal Cancer Candidate

Gritstone bio Inc GRTS announced updated overall survival (OS) results from its Phase 1/2 study evaluating GRANITE, an individualized vaccine-based immunotherapy for advanced solid tumors.
6 of 13 treated patients with metastatic, microsatellite stable colorectal cancer (MSS-CRC) had a molecular response. The observed overall survival in this group will now exceed 22 months (median OS not yet reached versus 7.8 months in those without a molecular response).
Related: Gritstone's Cancer Drug Shows Strong Tumor-Specific Responses In Various Settings.
This compares to a median overall survival not yet reached and exceeding 18 months, as reported in May 2022.
4 of 6 patients with molecular response had liver metastasis.
All patients had PD-L1 expression <1% and low levels of IFNg-related gene expression.
The median tumor mutational burden was 2.9 and 3.6 mutations/MB in those with and without molecular response, respectively.
Price Action: GRTS shares are up 10.85% at $2.61 on the last check Thursday.